Aug 11
XGN · Exagen Inc.
Market Cap
$184.11M
Shares
24.23M
Volume · Nov 5
411.7K
Avg daily vol (3M)
314.07K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.60
Open$8.43
Day$7.46–8.48
52W close$2.65–10.38
Avg vol 30d334K
Short int674K · 2.8% of shares · 1.8d
Short vol34%
Last earningsNov 10, 2026
DataJan 2020–Nov 2026
Filing10-Q · Aug 4
Up next
Nov 10, 2026
Announced
· in 1 wks
Nov 10, 2026
Scheduled
· in 1 wks
Latest documents
2026
Aug 4
Aug 4
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Revenue $19.94M
▲ 15.9%
Net loss $3.2M
Diluted EPS -$0.13
Aug 4
Jun 9
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$71.12M
Trailing 12 months
Net income (TTM)
−$18.92M
Trailing 12 months
Revenue growth YoY
+15.9%
Year over year
Operating margin
-18.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.75M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+14.6%
Year over year · more shares
Price change (1Y)
-21.0%
Trailing year
Short interest
2.8%
Latest settlement · 1.8 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Exagen reported record Q2 revenue of $19.9 million (+16% YoY), record AVISE CTD volume (+11% YoY) and trailing 12-month ASP of $446 (+4% YoY), and narrowed adjusted EBITDA loss to $0.1M; the company raised full-year 2026 revenue guidance to $72–$75M.
Bullish
- + Raised full-year 2026 revenue guidance to $72–$75M from $70–$73M
- + Q2 revenue hit a record $19.9M, up 16% YoY and 15% sequentially
- + Adjusted EBITDA loss narrowed to $0.1M from a $1.7M loss YoY, and net loss improved nearly 30%
- + Pharma services revenue crossed $1M for the first time (~$1M), up 200%+ YoY, with backlog up ~$1M to over $6M
Bearish
- − Management does not expect Q2's near-breakeven adjusted EBITDA to be sustained in H2 2026 due to typical seasonality
- − Reimbursement risk persists with no update on MolDX LCD; Medicare rate static while ASP growth depends on commercial payer progress
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.6 · calm
Equity put/call 0.44
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+49%
above
Price vs 50-day avg
−5%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
64%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+109%
trailing
YTD return
+25%
this year
Relative strength
+110%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Distributing
8 of 57 funds reported for Sep 30 · net -34.8K sh shares · +5 new
Insider flow
Distributing
Net -$418.6K over 90 days · 100% sells
Short interest
Falling
2.78% of shares out · ▼ -4.4% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
58%
contracting
EPS growth
−12%
Y/Y
Free cash flow
$-14.3M
Balance sheet
$9.3M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
7.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 4, 2026
Full-year revenue
· full year 2026
$72M – $75M
prior FY $66.58M
midpoint +10.4% Y/Y
Previous outlook
earlier release
· from the Earnings Call filed May 11, 2026
Still-open targets the latest release did not restate under the same label.
Annual guide
· annual
$70M – $73M
Guided vs delivered
· last 8 settled
Revenue
2025
guided $65M – $70M
$66.58M
In line
Full-year 2024 revenue
full year 2024
guided at least $57M
$55.64M
Miss −2.4%
Total revenue
first quarter 2024
guided $13M – $13.5M
$14.42M
Beat +8.8%
Full year 2023 revenue
full year 2023
guided at least $50M
$52.55M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+49%
Bullish
Price vs 50-day avg
−5%
Neutral
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
64%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Distributing
8 of 57 funds reported for Sep 30 · net -34.8K sh shares · +5 new
Insider flow
Distributing
Net -$418.6K over 90 days · 100% sells
Short interest
Falling
2.78% of shares out · ▼ -4.4% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
57 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $8 · 64%
Range high $10
vs 200-day avg +49%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -114K | Three Months Ended June 30, 2026 | — |
| AVISE CTD test volume growth | 11% | second quarter 2026 | — |
| Diagnostic testing supplies purchased from two suppliers (share of total) | 93% | the three months ended June 30, 2026 filing | — |
| Pharma services revenue | $1M | the second quarter of 2026 filing | — |
| Share of revenue related to AVISE® CTD test | 89% | the three months ended June 30, 2026 filing | — |
| Trailing-twelve-month ASP of AVISE® CTD tests (increase over same period in prior year) | 4% | the three months ended June 30, 2026 filing | — |
| Trailing-twelve-month average selling price (ASP) | $446 | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XGN
this stock
Exagen Inc.
|
$184.11M | +25.0% | +19.7% | — | 2.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$250.82B | +16.8% | +14.5% | 35.7 | 1.3% |
|
DHR
Danaher Corp
|
$165.28B | -1.1% | +8.5% | 38.4 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.04B | -0.9% | +10.4% | 47.1 | 2.4% |
|
NTRA
Natera, Inc.
|
$52.75B | +58.8% | -2.8% | — | 4.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XGN | -12.6% | -7.0% | +108.8% | -11.5% | +25.0% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | -7.9% | -1.7% | +109.6% | -8.5% | +17.5% |